ESG206
Sponsors
Shanghai Escugen Biotechnology Co., Ltd
Conditions
B-cell Lymphoid MalignanciesImmune Thrombocytopenia (ITP)Primary Sjögren SyndromeSystemic Lupus Erythematosus (SLE)
Phase 1
A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
WithdrawnNCT05263739
Start: 2025-12-31End: 2026-12-31Updated: 2025-09-12
A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies
CompletedNCT05822843
Start: 2023-08-02End: 2025-01-22Updated: 2025-09-12
A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia
RecruitingNCT06853444
Start: 2025-05-08End: 2027-04-30Target: 84Updated: 2025-05-16
Phase 2
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome
Not yet recruitingNCT07375524
Start: 2026-03-01End: 2028-06-30Target: 40Updated: 2026-02-03
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
Not yet recruitingNCT07760155
Start: 2026-09-01End: 2028-09-30Target: 40Updated: 2026-08-12